Management

Simon Pimstone, MBChB, Ph.D., FRCPC
Dr. Pimstone has served as our Chief Executive Officer since March 2018, and previously served as our President and Chief Executive Officer since January 2003. Since 2012, Dr. Pimstone has been a Consultant Physician at the University of British Columbia Hospital, Cardiology Clinic, and since 2014, he has held the position of Clinical Associate Professor at the University of British Columbia, Division of General Internal Medicine. Currently, Dr. Pimstone is an Investigator at the Centre for Heart Lung Innovation (HLI) research centre. Dr. Pimstone currently serves as chair of Eupraxia Pharmaceuticals Inc., a private specialty pharmaceutical company, where he has served as a director since 2012. Dr. Pimstone also sits on the BC Health Research Strategy Advisory Board of the Michael Smith Foundation for Health Research. Dr. Pimstone holds an MBChB from the University of Cape Town, a FRCPC from the University of British Columbia, and a Ph.D. from the University of Amsterdam in cardiovascular genetics. Dr. Pimstone is a former director of Indel Therapeutics Inc., Cyon Therapeutics Inc. and Enject, Inc. Previously, Dr. Pimstone was director and chair of the Board of Directors of LifeSciences British Columbia, a non-profit industry association that supports the life science community, and a former director of the Providence Healthcare Research Trust, BC Advantage Life Sciences Fund, Centre for Molecular Medicine and Therapeutics, and BIOTECanada.

Ian Mortimer, MBA, CPA, CMA
Ian Mortimer has served as our President and Chief Financial Officer since March 2018, and previously served as our Chief Financial Officer and Chief Operating Officer since March 2015 and additionally as Corporate Secretary since June 2015, and as our Chief Financial Officer since October 2013 when he joined Xenon. Prior to joining us, Mr. Mortimer served as Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (“Tekmira”) (now Arbutus Biopharma Corporation), a NASDAQ-listed biotechnology company, from 2007 until October 2013. Mr. Mortimer was responsible for all aspects of Tekmira’s finance and capital markets activities and led Tekmira’s listing on NASDAQ in 2010. From 2004 to 2007, Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals and held various other positions at Inex Pharmaceuticals from 1997 to 2004. Since November 2017, Mr. Mortimer has served on the Board of Directors and as Chair of the Audit Committee for Appili Therapeutics, a private biopharmaceutical company focused on developing treatments for infectious diseases. Mr. Mortimer has an M.B.A. from Queen’s University, a B.Sc. in Microbiology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management Accountant.

Ernesto Aycardi, M.D.
Dr. Aycardi has served as our Chief Medical Officer since March 2018. Dr. Aycardi joins Xenon with more than 20 years’ extensive experience in the pharmaceutical industry. Prior to joining us, Dr. Aycardi was at Teva Pharmaceutical Industries Ltd. (“Teva”) from 2014 to 2018, most recently as Vice-President and Head of Clinical Trial Operations, Biostatistics & Data Sciences and Clinical Pharmacology. Prior to this, he was the Vice-President of Clinical Development, TA Head of Migraine and Headache at Teva. From 2013 to 2014, Dr. Aycardi was Senior Director Head of late development of Neuro-Degenerative disorders for EMD Serono, Inc. Previously, he was Director, Medical Research focused on neurology development at Biogen Idec from 2009 to 2013. Dr. Aycardi held a series of roles with increasing responsibility at Merck & Co., Inc. from 1998 to 2009, both in Colombia and in the United States, where he was Worldwide Clinical Research Senior Director for various therapeutic areas throughout late phases of global drug development from 2006 to 2009. Having received his MD from the National University of Colombia, and neurology training at the Military Hospital in Colombia, Dr. Aycardi holds a current medical license in Colombia, and was a practicing neurologist beginning in 1993.

Robin Sherrington, Ph.D.
Dr. Sherrington has served as our Executive Vice President, Business & Corporate Development since March 2018, and previously served as our Senior Vice President, Business & Corporate Development since February 2012, as our Vice President, Business & Corporate Development from January 2010 to February 2012, and has held various positions in business development and other departments since joining us in March 2001. Prior to joining us, Dr. Sherrington worked at Pfizer, Inc., a global pharmaceutical company, as a neuroscientist from 1999 to 2001. Dr. Sherrington also previously served as Director of Neuroscience, from 1996 to 1999, at the biotechnology companies Axys Pharmaceuticals and Sequana Therapeutics. Prior to 1996 Dr. Sherrington was a post-doctoral fellow at University of Toronto and received his Ph.D. from the University College London, and his B.Sc. with honors from University of Reading.

James Empfield, Ph.D.
Dr. Empfield has served as our Senior Vice President, Drug Discovery since February 2016. Prior to joining us, Dr. Empfield served as Vice President, Drug Discovery and Chemistry; Co-Site Head of Research, Boston at Vertex from 2011 until August 2015. At Vertex, Dr. Empfield was jointly responsible for the entire Boston research organization and for delivery of lead optimization projects into preclinical development. From 2006 to 2011, Dr. Empfield was Director, CNS Chemistry Department at Astrazeneca Pharmaceuticals LP and held various other positions at Astrazeneca Pharmaceuticals from 1990 to 2006. Dr. Empfield has a Ph.D. in Chemistry from the University of Pennsylvania, a M.S. in Chemistry from Bucknell University and a B.Sc. in Chemistry from Lebanon Valley College.

Y. Paul  Goldberg, MBChB, Ph.D., FRCPC
Dr. Goldberg has served as our Senior Vice President, Clinical Development since March 2017, as our Vice President, Clinical Development since February 2010, as our Senior Director, Clinical Biology and Target Discovery from 2002 until February 2010, as our Senior Director, Scientific Programs from 2001 until 2002, and as our Director and Senior Scientist from 2000 until 2002. Since 2000 Dr. Goldberg has also worked at the University of British Columbia in the Department of Medical Genetics as a Medical Geneticist, Clinical Assistant Professor. Dr. Goldberg received his MBChB and Ph.D. from the University of Cape Town, and he obtained his specialization in clinical genetics, FRCPC from the University of British Columbia.

Charles Cohen, PhD
Dr. Cohen has served as our Vice President, Biology since January 2008. Prior to joining us, Dr. Cohen worked at Vertex Pharmaceuticals Inc. (“Vertex”) as a Research Fellow II from 2004 to 2008. In this position he led biology teams targeting neuropathic pain and neuroinflammation. From 1986 to 2004, Dr. Cohen worked at Merck Research Laboratories (“MRL”). From 2000 to 2004, he served as Director of Neuroscience and was world-wide coordinator of MRL’s research on multiple sclerosis and neuroinflammation. From 1986 to 2000, Dr. Cohen was a member of the Ion Channel department, advancing to the level of Senior Investigator. Prior to MRL, Dr. Cohen served as a Senior Scientist at Bayer Pharmaceuticals. Dr. Cohen received his Ph.D. in Biophysics and Theoretical Biology from the University of Chicago and received post-doctoral training in the Department of Cardiology at the University of Chicago and the Department of Physiology at Yale University.

Jodi Regts, BA, MBA
Jodi Regts has served as our Vice President, Corporate Affairs and Investor Relations since March 2017, and previously as our Senior Director, Corporate Affairs since December 2015. Ms. Regts brings over 15 years of experience in investor relations, corporate communications, strategic planning, and media relations for publicly traded companies, with a particular concentration within the life sciences sector over the last decade. Prior to joining us, Ms. Regts served as Director, Investor Relations at lululemon athletica inc., a NASDAQ-listed, healthy lifestyle inspired athletic apparel company from 2014 to 2015. Previously, Ms. Regts served as Director, Investor Relations at Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma Corporation), a NASDAQ-listed biotechnology company, from 2011 to 2014. She was Director, Communications at the Centre for Drug Research and Development from 2009 to 2011. Ms. Regts led investor relations at Forbes Medi-Tech Inc., a NASDAQ-listed biotechnology and nutraceuticals company from 2008 to 2009, and was Senior Manager, Investor Relations and Corporate Communications at Angiotech Pharmaceuticals, Inc. (now Surgical Specialties Corporation) from 2005 to 2008. Ms. Regts has a BA and an M.B.A. from the University of Victoria.